What is Omnipod®?
The Omnipod® 5 and Omnipod DASH® systems offer customisable continuous insulin delivery through a wearable and waterproof‡ patch pump, called a Pod.
With no multiple daily injections to interrupt your day, and no tubes to cause unwanted tangles, it’s time to discover the freedom of Pod Therapy.
Unlock the Power of Omnipod
Meet our tubeless, wearable Pod lineup
Omnipod 5: Our Hybrid Closed Loop System
Omnipod 5 is the first and only Hybrid Closed Loop (HCL) system that works with the leading sensor brands*.
Omnipod 5 makes automated† insulin adjustments every five minutes based on compatible glucose sensor readings*, to improve time in range while lowering HbA1c1,2. With a choice of sensor integration, you can experience the freedom of a Hybrid Closed Loop System without switching from your preferred sensor.
Omnipod DASH®: Simple, Tubeless Insulin Delivery
Simplify Life® with Omnipod DASH. Place the Pod on your body almost anywhere you would inject insulin for up to three days (72 hours) of continuous insulin delivery.
The Personal Diabetes Manager (PDM) communicates wirelessly with the Pod, so you can adjust your insulin doses discreetly and easily wherever you are, without the need for tubing.
Why Choose Omnipod?
Omnipod is designed to keep diabetes management simple and discreet.
Built for everyday wear
Tubeless
No tubes, no tangles.
Wearable
Place the Pod almost anywhere you’d normally inject insulin.
Waterproof‡
Shower, swim, or exercise without removing it.
Designed to support your diabetes management
Up to 3 days of continuous insulin delivery
Each Pod provides up to 72 hours of continuous insulin delivery, helping reduce daily interruptions by replacing up to 14 injections.*
Personalised dosing
Controlled through a handheld device with a built-in SmartBolus Calculator, taking the headache out of mealtime maths.
Explore whether Omnipod is right for you
Choosing an insulin pump is a big decision, and it helps to feel informed and confident. If you’re exploring your options, you can learn more about what life with Omnipod is like, decide whether it feels right for you, and find out how to access it.
Hear from our Podders
Omnipod 5 reduces the burden of diabetes, it increases your quality of life and I couldn’t have even imagined something like this when I was first diagnosed.
Lydia P.
Podder® since 2014
First impressions were and still are how easy it is to use and how much better life is now that I do not have to worry about multiple daily injections.
Russell M.
Omnipod® Ambassador
I was never a fan of needles and the fact that I can bolus for snacks without injecting has really helped me improve my results and given me the freedom to eat wherever and whenever I want.
Temi O.
Omnipod® Ambassador
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001. Mean HbA1c: ST vs. Omnipod 5 use in adults/adolescents (14-70 yrs) and children (6-13.9 yrs), respectively (7.16% vs 6.78% or 55 mmol/mol vs. 51 mmol/mol, P<0.0001; 7.67% vs 6.99% or 60mmol/mol vs 53 mmol/mol), P<0.0001. Mean time >10.0 mmol/L or >180mg/dL (12AM-
<6AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 32.1% vs. 20.7%; 42.2% vs 20.7%, P<0.0001, respectively. Mean time >10.0 mmol/L or >180mg/dL (6AM-<12AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 32.6% vs. 26.1%; 46.4% vs 33.4%, P<0.0001, respectively. Mean time <3.9 mmol/L or <70 mg/dL (12AM-<6AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 3.64% vs. 1.17%, P<0.0001; 2.51% vs. 1.78, P=0.0456, respectively. Mean time <3.9 mmol/L or <70 mg/dL (6AM-<12AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 2.64% vs. 1.37%, P<0.0001; 2.13% vs. 1.98%, P=0.2545, respectively.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5 system. Mean HbA1c as measured in very young children, ST vs. Omnipod 5 use:7.4% vs 6.9% or 57 mmol/ml vs. 53 mmol/mol; (P<0.0001). Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001. Mean time >10.0 mmol/L or >180mg/dL (12AM-<6AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 38.4% vs. 16.9%, P<0.0001, respectively. Mean time >10.0 mmol/L or >180mg/dL (6AM-<12AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.7% vs. 33.7%, P<0.0001, respectively. Mean time <3.9 mmol/L or <70 mg/dL (12AM-<6AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 3.41% vs. 2.13%, P=0.0185. Mean time <3.9 mmol/L or <70 mg/dL (6AM-<12AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 3.44% vs. 2.57%, P=0.0799.